Biotechnology

Thursday Oct 06, 2022 - 12:15 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today provided a recap of its concussion drug development program. Concussions affect millions worldwide and represent an ‘unmet’ medical need, while repetitive concussions can increase the risk of developing chronic traumatic encephalopathy (“CTE”) and other neuropsychiatric disorders. Since acquisition of the intellectual property and all rights to the drug on March 1,…

Thursday Oct 06, 2022 - 12:10 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Platform to Add 24/7 Heart Monitoring Capability

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced the expansion of its product portfolio pipeline to serve the growing cardiac device wearable technology market by bringing clinically relevant diagnostic information to patients and clinicians. According to the update, the product pipeline advancement allows for the addition of arrhythmia…

Thursday Oct 06, 2022 - 10:38 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cybin continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel drug candidates. The company has more than…

Tuesday Oct 04, 2022 - 3:47 pm

InvestorNewsBreaks – ROTH’s Healthcare Opportunities Conference to Showcase ~25 Carefully Selected Companies

ROTH Capital Partners, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Inaugural Healthcare Opportunities Conference in New York City on Oct. 6, 2022. The conference will feature approximately 25 public healthcare companies that have been selected by ROTH’s research analysts and provide C-level executives the opportunity to closely interact with pre-qualified institutional…

Monday Oct 03, 2022 - 1:20 pm

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Preparing for Ketamine Tech FDA Pre-Investigational New Drug Package

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is collaborating with Premier Consulting to prepare a pre-investigational new drug (“IND”) package and meeting request with the United States Food and Drug Administration (FDA) for SPC-26, the company’s novel topical formulation of ketamine for the treatment of fibromyalgia. The company is planning to pursue a 505(b)(2) regulatory…

Monday Oct 03, 2022 - 12:57 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company specializing in developing novel treatments for brain tumors, has focused on its lead drug candidate, Berubicin, to potentially treat glioblastoma (“GBM”). “CNS has since made significant headway, even receiving FDA Fast Track Designation, which now offers it an accelerated path to approval for Berubicin. ‘With this designation, we now have an accelerated pathway to approval for…

Friday Sep 30, 2022 - 2:41 pm

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Working to Make a Difference in Underserved Patient Populations

QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of childhood cancer on the rise, the work of QSAM is becoming increasingly important… According to Children’s Cancer Cause, in 2022, an estimated 10,470 children (from birth to 14 years) and…

Friday Sep 30, 2022 - 10:42 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of common stock, each at a public offering price of $5.00.…

Thursday Sep 29, 2022 - 12:21 pm

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). In addition, Nasdaq confirmed that Aditxt meets…

Wednesday Sep 28, 2022 - 1:13 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Activates First European Sites for Potentially Pivotal Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of…

Wednesday Sep 28, 2022 - 12:26 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trial. Odyssey’s trial involved administering its novel drug to treat concussion, PRV-002, to healthy human subjects. The drug was safe and well tolerated throughout the trial. “After reviewing the data from…

Thursday Sep 22, 2022 - 2:15 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002

Odyssey Health (OTC: ODYY) announced in August the completion and findings of cohort I of the multiday ascending dosing (“MAD”) stage of its ongoing phase I clinical trial showing that PRV-002 was safe and well tolerated. A recent article reads: “Additionally, pharmacokinetic (‘PK’) analysis of the data from the first cohort provided new information that supports the hypothesis that more drug is getting to the…

Wednesday Sep 21, 2022 - 11:01 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes…

Wednesday Sep 21, 2022 - 10:57 am

InvestorNewsBreaks — GATC Health Corporation Releases Report on Recent Analysis Showing New Platform Performs 11x Better Than Industry Standard

GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using its proprietary upgraded version 2.0 of its drug-discovery artificial intelligence (“AI”) platform, is reporting on its recently completed analysis. According to the release, the company’s upgraded drug-discovery platform forecasts drug-candidate success rate with 88% accuracy; the platform also predicts drug-failure rates with 84% accuracy. Biopharma companies can potentially save billions of…

Wednesday Sep 21, 2022 - 9:57 am

InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has closed on its recent public offering. The offering was comprised of 3,333,333 shares of common stock or common stock equivalents; the offering also included warrants to purchase up to 3,333,333 shares of common stock. The combined offering price to the public was $6 per share…

Tuesday Sep 20, 2022 - 3:12 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Releases New Video Exploring Its Technologies, Progress of AIMIGo(TM) Device

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. The company today announced that, in conjunction with its upcoming virtual roadshow webinar taking place at 4:30 p.m. ET on Tuesday, Sept. 20, 2022, it has released a new video that takes viewers behind the scenes for a featured look at…

Tuesday Sep 20, 2022 - 1:35 pm

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug development. The milestones were key in moving Cybin’s psychedelic programs…

Tuesday Sep 20, 2022 - 10:14 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, will be releasing its financial report for fiscal year 2022, the period ended June 30, 2022, later this month. The company has announced that it will release the financial report, along with business highlights, on Sept. 23, 2022. In addition, the company has announced a conference call and webcast to…

Friday Sep 16, 2022 - 1:46 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leading Charge to Find Potential Treatment Option for GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. “GBM is considered one of the most complex, deadly and treatment-resistant cancers. And although it is regarded as rare, between 12,000 and 15,000 Americans…

Thursday Sep 15, 2022 - 2:24 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting

Silo Pharma (OTCQB: SILOD), a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it will effect a 1-for-50 reverse split of its common stock. Effective at the open of business on Thursday, Sept. 15, 2022, the reverse stock split is in preparation for the planned listing of the company’s securities on the Nasdaq Capital Market (“Nasdaq”). The company’s common…

Thursday Sep 15, 2022 - 11:48 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Secures Additional IP Protection for Breakthrough ECG Patch Technology

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced issuance of its patent for a 12-lead electrocardiogram (“ECG”) patch monitor intended for detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia by the United States Patent and Trademark Office. According to the update, the innovation builds on HeartBeam’s growing…

Wednesday Sep 14, 2022 - 12:36 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter…

Wednesday Sep 14, 2022 - 9:53 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has closed on a private placement agreement with two healthcare-focused institutional investors. The agreement consisted of the issue and sale of 691,245 of INM common shares prices at $8.68 per share (or prefunded warrant in lieu thereof), totaling approximately $6 million. According to the announcement, INM also issued unregistered preferred…

Tuesday Sep 13, 2022 - 10:08 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety measures for the second cohort of its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to evaluate the company’s novel drug to treat concussion: PRV-002. During the trial, healthy human subjects received the drug in…

Monday Sep 12, 2022 - 9:50 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters into $6M Securities Purchase Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, has announced a private placement agreement with two healthcare-focused institutional investors. The agreement calls for the issuance and sale of 691,245 of INM common shares; the shares will be sold at a purchase price of $8.68 per share in a private placement priced according to Nasdaq guidelines. According to the…

Friday Sep 09, 2022 - 9:45 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Update on Company Objectives and Programs

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, is reporting an update on the company’s research/development and commercial activities. According to the update, the company is working to complete enrollment in a phase 2 clinical program in epidermolysis bullosa (‘EB’) by the end of 2023, to advance its R&D efforts on a preclinical drug candidate…

Thursday Sep 08, 2022 - 1:41 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. “After a flurry of research in the…

Wednesday Sep 07, 2022 - 1:15 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will present at the H.C. Wainwright 24th Annual Global Investment Conference. The event is being held in New York, New York, and virtually on Sept. 12-14, 2022. A video webcast of the…

Tuesday Sep 06, 2022 - 12:23 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Secures FDA and Health Canada Approval for Phase 2 Trial of FSD201

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced its receipt of a “Study May Proceed” letter for the Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its…

Wednesday Aug 31, 2022 - 10:57 am

InvestorNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly controlled subsidiary of Cybin,…

Tuesday Aug 30, 2022 - 9:57 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study…

Monday Aug 29, 2022 - 12:05 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned…

Friday Aug 26, 2022 - 1:10 pm

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion

Odyssey Health (OTC: ODYY), a medical device innovator and biopharmaceutical product developer, has been advancing a proposed solution for brain injury from concussive forces. “Odyssey Health’s novel compound PRV-002 is the combination of a device and the medicine it delivers to treat concussions during the first moments after their occurrence, before permanent or long-term damage can set in. No U.S. Food and Drug Administration (‘FDA’)-approved…

Thursday Aug 25, 2022 - 3:40 pm

InvestorNewsBreaks – BioLife Sciences Inc. (BLFE) Expands with Focus on Disruptive Hemp Products

BioLife Sciences (OTC: BLFE) has announced that it will be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on hemp products. According to the update, the company will focus on new and innovative product infusions centered around North American-grown, third-party tested industrial hemp with the intention to provide consumers with an array of new and more effective…

Thursday Aug 25, 2022 - 1:37 pm

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Receives ‘Marketable Advantage’ Toward Manufacturing, Supply Chain of CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs… The…

Thursday Aug 25, 2022 - 1:26 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research

Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder and chronic back pain,’”…

Thursday Aug 25, 2022 - 10:19 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the H.C. Wainwright 24th annual Global Investment Conference; the elite event is slated for Sept. 12–14, 2022. CYBN CEO Doug Drysdale will present in a virtual fireside chat during the conference. The company announced that his presentation will be available starting Sept. 12 at 7 a.m. ET.…

Tuesday Aug 23, 2022 - 1:27 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than one year post diagnosis. “The company’s lead drug candidate is…

Tuesday Aug 16, 2022 - 12:02 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured on “Dr. Finance Live,” a podcast series focused on changing the way we think about economics and finance. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the recent broadcast, hosted by best-selling author and entrepreneur Dr. Anthony M. Criniti IV…

Tuesday Aug 16, 2022 - 11:56 am

InvestorNewsBreaks – QSAM Biosciences Inc. (OTCQB: QSAM) Releases Q2 2022 Financial Report, Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June 30, 2022; the company also noted that progress has been shown in its phase 1 clinical program designed to evaluate CycloSam, its proprietary radiopharmaceutical drug candidate for the treatment of…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions